<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119649</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG2222-CL-202</org_study_id>
    <nct_id>NCT03119649</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled,
      parallel-group study to evaluate 4 different doses of GLPG2222 administered for 4 weeks to
      adult subjects with a confirmed diagnosis of CF and homozygous for the F508del CFTR mutation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2017</start_date>
  <completion_date type="Actual">October 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability assessments determined by number of subjects with adverse events</measure>
    <time_frame>from baseline up to day 43 (final FU visit)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG2222 as compared to placebo in terms of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sweat chloride concentration</measure>
    <time_frame>from baseline up to day 29</time_frame>
    <description>To evaluate the effect of GLPG2222 on CFTR activity as compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline of FEV1 (L) for age, gender and height as assessed by spirometry</measure>
    <time_frame>from baseline up to day 29</time_frame>
    <description>To evaluate the effect of GLPG2222 on respiratory symptoms as compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent predicted FEV1 for age, gender and height as assessed by spirometry</measure>
    <time_frame>from baseline up to day 29</time_frame>
    <description>To evaluate the effect of GLPG2222 on respiratory symptoms as compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the respiratory domain of Revised Cystic Fibrosis Questionnaire (CFQ-R)</measure>
    <time_frame>from baseline up to day 29</time_frame>
    <description>To evaluate the effect of GLPG2222 on respiratory symptoms as compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum observed plasma concentration) of GLPG2222</measure>
    <time_frame>pre-dose on day 15 and on day 29</time_frame>
    <description>To evaluate the PK of GLPG2222</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cthrough (plasma concentration observed at pre-dose)</measure>
    <time_frame>pre-dose on day 15 and on day 29</time_frame>
    <description>To evaluate PK of GLPG2222</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time to the occurrence of Cmax)</measure>
    <time_frame>pre-dose on day 15 and on day 29</time_frame>
    <description>To evaluate PK of GLPG2222</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(t) (area under the plasma concentration-time curve over the dosing interval)</measure>
    <time_frame>pre-dose on day 15 and on day 29</time_frame>
    <description>To evaluate PK of GLPG2222</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>GLPG2222 dose 1 for cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG2222 dose 2 for cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for cohort A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG2222 dose 1 for cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG2222 dose for cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for cohort B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG2222 dose 1 for cohort A</intervention_name>
    <description>One oral tablet containing GLPG2222 and two oral tablets containing placebo</description>
    <arm_group_label>GLPG2222 dose 1 for cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG2222 dose 2 for cohort A</intervention_name>
    <description>one oral tablet containing GLPG2222 and two oral tablets containing placebo</description>
    <arm_group_label>GLPG2222 dose 2 for cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1</intervention_name>
    <description>Three oral tablets q.d.containing placebo</description>
    <arm_group_label>Placebo for cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG2222 dose 1 for cohort B</intervention_name>
    <description>Two oral tablets containing GLPG2222 each and one oral tablet containing placebo</description>
    <arm_group_label>GLPG2222 dose 1 for cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG2222 dose 2 for cohort B</intervention_name>
    <description>Two oral tablets containing GLPG2222 and one oral tablet containing GLPG2222</description>
    <arm_group_label>GLPG2222 dose for cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2</intervention_name>
    <description>Three oral tablets q.d. containing placebo</description>
    <arm_group_label>Placebo for cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject ≥ 18 years of age, on the day of signing the Informed Consent
             Form (ICF).

          2. A confirmed clinical diagnosis of CF and homozygous for the F508del CFTR mutation

          3. Weight ≥ 40 kg.

          4. Stable concomitant treatment for at least 4 weeks (28 days) prior to baseline

          5. Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted normal for age, gender
             and height at screening

        Exclusion Criteria:

          1. History of clinically meaningful unstable or uncontrolled chronic disease that makes
             the subject unsuitable for inclusion in the study in the opinion of the investigator.

          2. Unstable pulmonary status or respiratory tract infection requiring a change in therapy
             within 4 weeks of baseline.

          3. Need for supplemental oxygen during the day, and &gt;2 liters per minute (LPM) while
             sleeping.

          4. Use of CFTR modulator therapy (e.g. lumacaftor or ivacaftor) within 4 weeks prior to
             the first study drug administration.

          5. History of hepatic cirrhosis with portal hypertension.

          6. Abnormal liver function test at screening; defined as aspartate aminotransferase (AST)
             and/or alanine aminotransferase (ALT) and/ or alkaline phosphatase and/or total
             bilirubin (&gt;1.5 times ULN (CTCAE Grade 2) and/or gamma-glutamyl transferase (GGT) ≥ 3x
             the upper limit of normal (ULN), and/or total bilirubin (&gt;1.5 times ULN (CTCAE Grade
             2).

          7. Estimated creatinine clearance &lt; 60mL/min using the Cockroft-Gault formula at
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Van Steen, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Child Health Research Unit at UAB</name>
      <address>
        <city>Chatom</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center of Chicago</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus medisch centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mother and child health institute of Serbia</name>
      <address>
        <city>Novi Beograd</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitarii Plitecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton general Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

